The role of local tissue renin-angiotensin system (tRAS) activation in the cardiorenal metabolic syndrome (CRS) and type 2 diabetes mellitus (T2DM) is not well understood. To this point, we posit that early redox stress-mediated injury to tissues and organs via accumulation of excessive reactive oxygen species (ROS) and associated wound healing responses might serve as a paradigm to better understand how tRAS is involved. There are at least five common categories responsible for generating ROS that may result in a positive feedback ROS-tRAS axis. These mechanisms include metabolic substrate excess, hormonal excess, hypoxia-ischemia/reperfusion, trauma, and inflammation. Because ROS are toxic to proteins, lipids, and nucleic acids they may be the primary instigator, serving as the injury nidus to initiate the wound healing process. Insulin resistance is central to the development of the CRS and T2DM, and there are now thought to be four major organ systems important in their development. In states of overnutrition and tRAS activation, adipose tissue, skeletal muscle (SkM), islet tissues, and liver (the quadrumvirate) are individually and synergistically related to the development of insulin resistance, CRS, and T2DM. The obesity epidemic is thought to be the driving force behind the CRS and T2DM, which results in the impairment of multiple end-organs, including the cardiovascular system, pancreas, kidney, retina, liver, adipose tissue, SkM, and nervous system. A better understanding of the complex mechanisms leading to local tRAS activation and increases in tissue ROS may lead to new therapies emphasizing global risk reduction of ROS resulting in decreased morbidity and mortality.

1.
Basso N, Terragno NA: History about the discovery of the renin-angiotensin system. Hypertension 2001;38:1246–1249.
2.
Dietze GJ, Henriksen EJ: Angiotensin-converting enzyme in skeletal muscle: sentinel of blood pressure control and glucose homeostasis. J Renin Angiotensin Aldosterone Syst 2008;9:75–88.
3.
Célérier J, Schmid G, Le Caer JP, Gimenez-Roqueplo AP, Bur D, Friedlein A, Langen H, Corvol P, Jeunemaitre X: Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. J Biol Chem 2000;275:10648–10654.
4.
Imai T, Miyazaki H, Hirose S, Hori H, Hayashi T, Kageyama R, Ohkubo H, Nakanishi S, Murakami K: Cloning and sequence analysis of cDNA for human renin precursor. Proc Natl Acad Sci USA 1983;80:7405–7409.
5.
Lanzillo JJ, Stevens J, Dasarathy Y, Yotsumoto H, Fanburg BL: Angiotensin-converting enzyme from human tissues. Physicochemical, catalytic, and immunological properties. J Biol Chem 1985;260:14938–14944.
6.
Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747–803.
7.
Paul M, Bachmann J, Ganten D: The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc Med 1992;2:94–99.
8.
Campbell DJ: Tissue renin-angiotensin system: sites of angiotensin formation. J Cardiovasc Pharmacol 1987;10(suppl 7):S1–S8.
9.
Lindpaintner K, Ganten D: Tissue renin-angiotensin systems and their modulation: the heart as a paradigm for new aspects of converting enzyme inhibition. Cardiology 1991;79(suppl 1):32–44.
10.
Dzau VJ, Re R: Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994;89:493–498.
11.
Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77(6 Pt 2):I3–I14.
12.
Johnston CI: Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 1992;10:S13–S26.
13.
Kumar R, Singh VP, Baker KM: The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 2007;18:208–214.
14.
Sharma AM, Engeli S: The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:29–35.
15.
Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270–1277.
16.
Montgomery H, Humphries SE, Leung PS: Renin-angiotensin system: the new frontier. Int J Biochem Cell Biol 2003;35:758.
17.
Lau T, Carlsson PO, Leung PS: Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004;47:240–248.
18.
Leung PS: The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007;580:31–37.
19.
Lubel JS, Herath CB, Burrell LM, Angus PW: Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 2008;23:1327–1338.
20.
Savaskan E: The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res 2005;2:29–35.
21.
McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FAO, Chai SY: The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003;35:901–918.
22.
Higashimori K, Gante J, Holzemann G, Inagami T: Significance of vascular renin for local generation of angiotensins. Hypertension 1991;17:270–277.
23.
Carey RM, Siragy HM: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24:261–271.
24.
Peters H, Unger T: Mast cells and the power of local RAS activation. Nephrol Dial Transplant 2007;22:40–42.
25.
Jin M, Wilhelm MJ, Lang RE, Unger T, Lindpaintner K, Ganten D: Endogenous tissue renin-angiotensin systems. From molecular biology to therapy. Am J Med 1988;84:28–36.
26.
Cooper ME: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004;17(11 Pt 2):16S–20S.
27.
Wookey PJ, Cao Z, Cooper ME: Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension. Miner Electrolyte Metab 1998;24:389–399.
28.
Bachmann S, Peters J, Engler E, Ganten D, Mullins J: Transgenic rats carrying the mouse renin gene – morphological characterization of a low-renin hypertension model. Kidney Int 1992;41:24–36.
29.
Hayden MR, Karuparthi PR, Habibi J, Wasekar C, Lastra G, Manrique C, Stas S, Sowers JR: Ultrastructural islet study of early fibrosis in the Ren2 rat model of hypertension. Emerging role of the islet pancreatic pericyte-stellate cell. JOP 2007;8:725–738.
30.
Hayden MR, Sowers JR: Isletopathy in type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal 2007;9:891–910.
31.
Ganten D, Marquez-Julio A, Granger P, Hayduk K, Karsunky KP, Boucher R, Genest J: Renin in the dog brain. Am J Physiol 1971;221:1733–1737.
32.
Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H: Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol 2008;35:922–927.
33.
Clark RA: Cutaneous tissue repair: basic biologic considerations. J Am Acad Dermatol 1985;13(5 Pt 1):701–725.
34.
Clark RA: The commonality of cutaneous wound repair and lung injury. Chest 1991;99(3 suppl):57S–60S.
35.
Hayden MR, Patel K, Habibi J, Gupta D, Tekwani SS, Whaley-Connell A, Sowers JR: Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr 2008;3:234–243.
36.
Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003;2:2.
37.
Habibi J, Whaley-Connell A, Hayden MR, DeMarco VG, Schneider R, Sowers SD, Karuparthi P, Ferrario CM, Sowers JR: Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008;149:5643–5653.
38.
Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR: Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007;148:3773–3780.
39.
Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, Hayden MR, Wei Y, Ferrario C, Sowers JR: Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008;295:E110–E116.
40.
Hayden MR, Chowdhury N, Govindarajan G, Karuparthi PR, Habibi J, Sowers JR: Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:326–333.
41.
Hayden MR, Tyagi SC: Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol 2002;1:3.
42.
Hayden MR, Tyagi SC: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 2004;3:4.
43.
Hayden MR, Tyagi SC: Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 2004;1:10.
44.
Hayden MR, Sowers JR: Hypertension in type 2 diabetes mellitus. Insulin 2006;1:22–37.
45.
Hayden MR, McGowan BS: Understanding the links between insulin resistance, diabetes, and cardiovascular risk. Practical Diabetol 2005;24:6–14.
46.
Hayden MR, Whaley-Connell A, Sowers JR: Role of angiotensin II in diabetic cardiovascular and renal disease. Curr Opin Endocrinol Diabetes 2006;13:135–140.
47.
Chan WP, Fung ML, Nobiling R, Leung PS: Activation of local renin-angiotensin system by chronic hypoxia in rat pancreas. Mol Cell Endocrinol 2000;160:107–114.
48.
Nangaku M, Fujita T: Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 2008;31:175–184.
49.
Matoba S, Tatsumi T, Natsuya Keira N, Kawahara A, Akashi K, Kobara M, Asayama J, Nakagawa M: Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circulation 1999;99:817–822.
50.
Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, Arteel GE: Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 2004;40:583–589.
51.
Gorbunov NV, Elsayed NM, Kisin ER, Kozlov AV, Kagan VE:Air blast-induced pulmonary oxidative stress: interplay among hemoglobin, antioxidants, and lipid peroxidation. Am J Physiol1997;272:L320–L334.
52.
Järvinen TA, Järvinen TL, Kääriäinen M, Kalimo H, Järvinen M: Muscle injuries: biology and treatment. Am J Sports Med 2005;33:745–764.
53.
Tavazzi B, Vagnozzi R, Signoretti S, Amorini AM, Belli A, Cimatti M, Delfini R, Di Pietro V, Finocchiaro A, Lazzarino G: Temporal window of metabolic brain vulnerability to concussions: oxidative and nitrosative stresses – part II. Neurosurgery 2007;61:390–395, discussion 395–396.
54.
Tsuchiya M, Sato EF, Inoue M, Asada A: Open abdominal surgery increases intraoperative oxidative stress: can it be prevented? Anesth Analg 2008;107:1946–1952.
55.
Glantzounis GK, Tselepis AD, Tambaki AP, Trikalinos TA, Manataki AD, Galaris DA, Tsimoyiannis EC, Kappas AM: Laparoscopic surgery-induced changes in oxidative stress markers in human plasma. Surg Endosc 2001;15:1315–1319.
56.
Ohta Y, Kongo-Nishikawa M, Imai Y, Kishikawa T: Contribution of xanthine oxidase-derived oxygen free radicals to the development of carbon tetrachloride-induced acute liver injury in rats. J Clin Biochem Nutr 2003;33:89–93.
57.
Sakurai K, Katoh M, Someno K, Fujimoto Y: Apoptosis and mitochondrial damage in INS-1 cells treated with alloxan. Biol Pharm Bull 2001;24:876–882.
58.
Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel ML: Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islet. Biochem Biophys Res Commun 1993;197:1458–1464.
59.
Zhao W, Diz DI, Robbins ME: Oxidative damage pathways in relation to normal tissue injury. Br J Radiol 2007;80:S23–S31.
60.
Robbins ME, Diz DI: Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006;64:6–12.
61.
Gloire G, Legrand-Poels S, Piette J: NF-ĸB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006;72:1493–1505.
62.
DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985;76:149–155.
63.
Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Järvinen H, Christin L, Secomb TW, Bogardus C: Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987;80:415–424.
64.
DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667–687.
65.
Nistala R, Stump CS: Skeletal muscle insulin resistance is fundamental to the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:47–52.
66.
Agoudemos MM, Greene AS: Localization of the renin-angiotensin system components to the skeletal muscle microcirculation. Microcirculation 2005;12:627–636.
67.
Faust IM, Johnson PR, Stern JS, Hirsch J: Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol 1978;235:E279–E286.
68.
Klyde BJ, Hirsch J: Increased cellular proliferation in adipose tissue of adult rats fed a high-fat diet. J Lipid Res 1979;20:705–715.
69.
Klyde BJ, Hirsch J: Isotopic labeling of DNA in rat adipose tissue: evidence for proliferating cells associated with mature adipocytes. J Lipid Res 1979;20:691–704.
70.
Goossens GH, Blaak EE, van Baak MA: Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003;4:43–55.
71.
Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609–611.
72.
Darimont C, Avanti O, Blancher F, Wagniere S, Mansourian R, Zbinden I, Leone-Vautravers P, Fuerholz A, Giusti V, Macé K: Contribution of mesothelial cells in the expression of inflammatory-related factors in omental adipose tissue of obese subjects. Int J Obes (Lond) 2008;32:112–120.
73.
Henegar C, Tordjman J, Achard V, Lacasa D, Cremer I, Guerre-Millo M, Poitou C, Basdevant A, Stich V, Viguerie N, Langin D, Bedossa P, Zucker JD, Clement K: Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 2008;9:R14.
74.
Hayden MR: Calciphylaxis and the cardiometabolic syndrome: the emerging role of sodium thiosulfate as a novel treatment option. J Cardiometab Syndr 2008;3:55–59.
75.
Sowers KM, Hayden MR: Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010;3:109–121.
76.
Bergman RN, Ader M: Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351–356.
77.
Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–438.
78.
Ludwig J, McGill DB, Lindor KD: Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;12:398–403.
79.
Hayden MR, Stump CS, Sowers JR: Introduction: organ involvement in the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:16–24.
80.
Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA: Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:36–40.
81.
Cortez-Pinto H, de Moura MC, Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006;44:197–208.
82.
Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA: Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008;49:417–428.
83.
Tolman KG, Dalpiaz AS: Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag 2007;3:1153–1163.
84.
Toblli JE, Muñoz MC, Cao G, Mella J, Pereyra L, Mastai R: ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008;16:770–776.
85.
Leung PS, Chappell MC: A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol 2003;35:838–846.
86.
Leung PS, de Gasparo M: Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr 2006;1:197–203.
87.
Hayden MR: Islet amyloid and fibrosis in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2007;2:70–75.
88.
Hayden MR, Sowers JR: Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens 2008;2:239–266.
89.
Hayden MR, Karuparthi PR, Habibi J, Lastra G, Patel K, Wasekar C, Manrique CM, Ozerdem U, Stas S, Sowers JR: Ultrastructure of islet microcirculation, pericytes and the islet exocrine interface in the HIP rat model of diabetes. Exp Biol Med (Maywood) 2008;233:1109–1123.
90.
Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC: Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 2004;53:1509–1516.
91.
Matveyenko AV, Butler PC: β-Cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 2006;55:2106–2114.
92.
Matveyenko AV, Butler PC: Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J 2006;47:225–233.
93.
Zhao HL, Sui Y, Guan J, He L, Gu XM, Wong HK, Baum L, Lai FM, Tong PC, Chan JC: Amyloid oligomers in diabetic and nondiabetic human pancreas. Transl Res 2009;153:24–32.
94.
Zhao HL, Lai FM, Tong PC, Zhong DR, Yang D, Tomlinson B, Chan JC: Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 2003;52:2759–2276.
95.
Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME: Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004;53:989–997.
96.
von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH: Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994;89:458–470.
97.
Rossi GP, Sacchetto A, Cesari M, Pessina AC: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300–307.
98.
Seccia TM, Belloni, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP: Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003;41:666–673.
99.
Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976–1982.
100.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
101.
Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J: The EPHESUS Trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79–87.
102.
Dostal DE: The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 2000;91:1–11.
103.
Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, Sukhova GK, Wolters PJ, Du J, Gorgun CZ, Doria A, Libby P, Blumberg RS, Kahn BB, Hotamisligil GS, Shi GP: Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009;15:940–945.
104.
Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R: Mast cells: a unique source of renin. Proc Natl Acad Sci USA 2004;101:13607–13612.
105.
Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033–1079.
106.
Holdsworth SR, Summers SA: Role of mast cells in progressive renal diseases. J Am Soc Nephrol 2008;9:2254–2261.
107.
Whaley-Connell A, Pulakat L, DeMarco VG, Hayden MR, Habibi J, Henriksen EJ, Sowers JR: Overnutrition and the cardiorenal syndrome: use of a rodent model to examine mechanisms. Cardiorenal Med 2011;1:23–30.
108.
Hayden MR, Tyagi SC: Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 2002;3:86–108.
109.
Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003;9:SR35–SR52.
110.
Prasad A, Quyyumi AA: Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004;110:1507–1512.
111.
Hayden MR, Whaley-Connell A, Sowers JR: Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005;25:553–569.
112.
Hayden MR, Chowdhury NA, Cooper SA, Whaley-Connell A, Habibi J, Witte L, Wiedmeyer C, Manrique CM, Lastra G, Ferrario C, Stump C, Sowers JR: Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2007;292:F861–F867.
113.
Hayden MR, Tyagi SC: Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit 2004;10:RA291–RA307.
114.
De Nuccio I, Salvati G, Genovesi G, Paolini P, Marcellini L, Schiavello V, Re M: Physiopathology of the renin-angiotensin system in the ovary. Minerva Endocrinol 1999;24:77–81.
115.
Brunswig-Spickenheier B, Mukhopadhyay AK: Local regulatory factors in regulation of ovarian function: role of prorenin-renin-angiotensin-system. Indian J Exp Biol 2003;41:669–681.
116.
Strain WD, Chaturvedi N: The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst 2002;3:243–246.
117.
Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ: The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003;20:607–621.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.